Song L, Zhu C, Shi Q, Xia Y, Liang X, Qin W
EBioMedicine. 2024; 109:105436.
PMID: 39476535
PMC: 11567102.
DOI: 10.1016/j.ebiom.2024.105436.
Ismail A, Tanasova M
Int J Mol Sci. 2022; 23(15).
PMID: 35955833
PMC: 9368955.
DOI: 10.3390/ijms23158698.
Kim H, Shim B, Lee S, Lee J, Lee H, Kim I
Int J Mol Sci. 2021; 22(18).
PMID: 34575959
PMC: 8470481.
DOI: 10.3390/ijms22189795.
Ogorevc M, Strikic A, Zekic Tomas S
Biomed Rep. 2021; 15(4):79.
PMID: 34429965
PMC: 8372117.
DOI: 10.3892/br.2021.1455.
Chen X, Zhao Y, Lyu S, Gao G, Gao Y, Qi Y
Invest New Drugs. 2021; 39(5):1242-1255.
PMID: 33900490
DOI: 10.1007/s10637-021-01109-2.
Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Karivedu V, Jain A, Eluvathingal T, Sidana A
Curr Urol Rep. 2019; 20(10):56.
PMID: 31468240
DOI: 10.1007/s11934-019-0932-2.
Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy.
Zambrano A, Molt M, Uribe E, Salas M
Int J Mol Sci. 2019; 20(13).
PMID: 31324056
PMC: 6651361.
DOI: 10.3390/ijms20133374.
Conformational Studies of Glucose Transporter 1 (GLUT1) as an Anticancer Drug Target.
Almahmoud S, Wang X, Vennerstrom J, Zhong H
Molecules. 2019; 24(11).
PMID: 31181707
PMC: 6600248.
DOI: 10.3390/molecules24112159.
Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications.
Kobayashi M, Uematsu T, Tokura Y, Takei K, Sakamoto K, Narimatsu T
Int Braz J Urol. 2018; 45(1):169-178.
PMID: 30521176
PMC: 6442141.
DOI: 10.1590/S1677-5538.IBJU.2018.0271.
Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases.
Dura M, Nemejcova K, Jaksa R, Bartu M, Kodet O, Ticha I
Pathol Oncol Res. 2017; 25(1):361-368.
PMID: 29128957
DOI: 10.1007/s12253-017-0363-7.
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.
Siebeneicher H, Cleve A, Rehwinkel H, Neuhaus R, Heisler I, Muller T
ChemMedChem. 2016; 11(20):2261-2271.
PMID: 27552707
PMC: 5095872.
DOI: 10.1002/cmdc.201600276.
Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.
Sun J, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F
Am J Cancer Res. 2015; 5(7):2139-55.
PMID: 26328245
PMC: 4548326.
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
Schodel J, Grampp S, Maher E, Moch H, Ratcliffe P, Russo P
Eur Urol. 2015; 69(4):646-657.
PMID: 26298207
PMC: 5012644.
DOI: 10.1016/j.eururo.2015.08.007.
Targeting glycogen metabolism in bladder cancer.
Ritterson Lew C, Guin S, Theodorescu D
Nat Rev Urol. 2015; 12(7):383-91.
PMID: 26032551
PMC: 4678000.
DOI: 10.1038/nrurol.2015.111.
Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma.
Yamasaki T, Seki N, Yoshino H, Itesako T, Yamada Y, Tatarano S
Cancer Sci. 2013; 104(11):1411-9.
PMID: 23889809
PMC: 7654250.
DOI: 10.1111/cas.12240.
Crossing paths in Human Renal Cell Carcinoma (hRCC).
Gallego G, Villaamil V, Grande E, Cainzos I, Anton Aparicio L
Int J Mol Sci. 2012; 13(10):12710-33.
PMID: 23202921
PMC: 3497295.
DOI: 10.3390/ijms131012710.
Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder.
Reis H, Tschirdewahn S, Szarvas T, Rubben H, Schmid K, Grabellus F
Oncol Lett. 2012; 2(6):1149-1153.
PMID: 22848280
PMC: 3406550.
DOI: 10.3892/ol.2011.394.
The Glycolytic Phenotype is Correlated with Aggressiveness and Poor Prognosis in Invasive Ductal Carcinomas.
Jang S, Han H, Jang K, Jun Y, Jang S, Min K
J Breast Cancer. 2012; 15(2):172-80.
PMID: 22807934
PMC: 3395740.
DOI: 10.4048/jbc.2012.15.2.172.
Development of a novel class of glucose transporter inhibitors.
Wang D, Chu P, Yang C, Yan R, Chuang Y, Kulp S
J Med Chem. 2012; 55(8):3827-36.
PMID: 22468970
PMC: 3375382.
DOI: 10.1021/jm300015m.
GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker.
Carvalho K, Cunha I, Rocha R, Ayala F, Cajaiba M, Begnami M
Clinics (Sao Paulo). 2011; 66(6):965-72.
PMID: 21808860
PMC: 3129958.
DOI: 10.1590/s1807-59322011000600008.